MYC amplification is common in Group 3 medulloblastoma and is associated with poor survival. Group 3 and Group 4 medulloblastomas are also known to have elevated levels of histone H3-lysine 27-tri-methylation (H3K27me3), at least in part due to high expression of the H3K27 methyltransferase enhancer of zest homologue 2 (EZH2), which can be regulated by MYC. We therefore examined whether MYC expression is associated with elevated EZH2 and H3K27me3 in medulloblastoma, and if high-MYC medulloblastomas are particularly sensitive to pharmacological EZH2 blockade. Western blot analysis of low (DAOY, UW228, CB SV40) and high (DAOY-MYC, UW228-MYC, CB-MYC, D425) MYC cell lines showed that higher levels of EZH2 and H3K27me3 were associated with elevated MYC. In fixed medulloblastoma samples examined using immunohistochemistry, most MYC positive tumors also had high H3K27me3, but many MYC negative ones did as well, and the correlation was not statistically significant. All high MYC lines tested were sensitive to the EZH2 inhibitor EPZ6438. Many low MYC lines also grew more slowly in the presence of EPZ6438, although DAOY-MYC cells responded more strongly than parent DAOY cultures with lower MYC levels. We find that higher MYC levels are associated with increased EZH2, and pharmacological blockade of EZH2 is a potential therapeutic strategy for aggressive medulloblastoma with elevated MYC.
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INTRODUCTION
Medulloblastoma is the most common malignant brain tumor in the pediatric population. Molecular analyses have revealed four distinct major groups of medulloblastomas: Wingless/Integrated (WNT)-activated, sonic hedgehog (SHH)-activated, Group 3 and Group 4.
1 Group 3 medulloblastomas are associated with very poor clinical outcomes, 2, 3 and often display increased copy numbers at the MYC locus and increased expression of MYC messenger RNA (mRNA) and protein. 4 Group 3 and Group 4 medulloblastomas are also known to have high levels of histone H3-lysine 27 tri-methylation (H3K27me3) 5, 6 due to high expression of the H3K27 methyltransferase, enhancer of zest homologue 2 (EZH2) or mutation of H3K27 demethylases. 6, 7 MYC is known to cause increased expression of EZH2 in prostate cancer, both directly and through downregulation of miR-26a and miR-26b, which are known to inhibit EZH2. 5 However, it is not known whether MYC upregulates EZH2 in medulloblastomas, or if EZH2 inhibitors might be effective in Group 3 medulloblastoma with high MYC levels. We therefore explored whether MYC upregulates EZH2 in medulloblastoma, and investigated pharmacological EZH2 blockade as a potential therapeutic strategy for aggressive medulloblastoma.
METHODS
Cell culture conditions and drug preparation 
Quantitative real-time polymerase chain reaction analyses
RNA extracted was carried out using the PureLink RNA Mini Kit (Thermo Fischer Scientific) with on-column DNA digestion to prevent amplification of genomic DNA. Reverse transcription into complementary DNA (cDNA) was performed. cDNA levels were analyzed by quantitative real-time polymerase chain reaction (qPCR) analysis with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) on an iQ5 Multicolor real-time PCR detection system. Standard curves were used to determine baseline expression levels and all values were normalized to β-actin. Relative EZH2 and MYC mRNA expression after treatment with EZH2 inhibitors was assessed using the ΔΔ-CT method. Statistical comparisons are between at least three biological replicates, each with triplicate technical replicates. Primer sequences were as follows: EZH2 forward: AGTGTGAC CCTGACCTCTGT, reverse: AGATGGTGCCAGCA ATAGAT; MYC forward: TTTCGGGTAGTGGAA AACCA; reverse: CACCGAGTCGTAGTCGAGGT; β-actin forward: CCCAGCACAATGAAGATCAA, reverse: CGATCCACACGGAGTACTTG.
Human tissue microarray
Tissue microarrays (TMAs) containing primary medulloblastomas obtained from the Department of Pathology, Johns Hopkins University School of Medicine, with institutional review board approval, 8 were created by the Johns Hopkins microarray core facility (core diameter 0.6 mm). These TMAs were stained for MYC (Epitomics #1472-1) at a dilution of 1:200, 12 and H3K27me3 (Abcam #ab6002) as previously described. 13 Each tumor was scored by intensity of MYC protein nuclear staining using a three-tiered scoring system (1: low staining; 2: moderate staining; 3: marked staining) ( Fig. 2A) by two boardcertified pathologists (FJR and CGE) blinded to clinical variables or status of other molecular markers. 8 Determination of cell growth 
Statistical analysis
Differences between three or more groups were assessed using one way analysis of variance (ANOVA) test with post hoc Tukey's multiple comparison test. Error bars represent standard error of means. All statistical tests were performed using the GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). P-values less than 0.05 were considered statistically significant.
RESULTS
Increased levels of EZH2 and H3K27me3 are found in medulloblastoma with elevated MYC levels
We investigated expression of EZH2 protein and H3K27 trimethylation in the D425 medulloblastoma line known to have high MYC levels due to amplification. 16 These cells have previously been used as models of Group 3 medulloblastoma. We also examined DAOY and UW228 medulloblastoma lines with very low baseline levels of MYC, as well as paired cultures stably transduced with vectors constitutively expressing MYC (DAOY-MYC and UW228-MYC). 8 Finally,
we evaluated human cerebellar neural stem cells transformed with either SV40 or MYC. 4 Western blot analysis showed relatively high EZH2 expression and H3K27 trimethylation in the D425 line. In each of the three paired models, elevation of EZH2 and H3K27me3 was seen in the MYC induced cells as compared to their low MYC counterparts (Fig. 1A) .
We also assessed baseline mRNA EZH2 expression in all cell lines (Fig. 1B) .
Consistent with protein level data, EZH2 mRNA expression was high in D425, and higher in DAOY-MYC 
H3K27me3 is elevated in Group 3 and Group 4 medulloblastomas
Having found that H3K27me3 correlates with high MYC expression in medulloblastoma cell lines, we next examined H3K27me3 levels in surgically obtained medulloblastoma samples. A tissue microarray was stained for H3K27me3, and 34 medulloblastoma cases had multiple cores, which were evaluable and also had a known molecular subgroup. Consistent with prior reports, relatively high levels were found in Group 3 and Group 4 medulloblastomas, although many SHH-activated cases showed significant expression as well (Fig. 2B,   7 ). H3K27me3 overall was decreased in normal cerebellar tissue compared to medulloblastoma, but positive staining was noted in granule cells. We had previously reported MYC protein expression using immunohistochemistry in this TMA, but MYC-positive cases had only slightly higher mean levels of H3K27me3, and the correlation with H3K27me3 was not statistically significant.
MYC knockdown decreases EZH2 expression
To further evaluate MYC regulation of EZH2 in medulloblastoma, we performed knockdown of MYC in D425 using siRNA. EZH2 protein expression was decreased by almost 30% 72 h after transfection (Fig. 3A) and EZH2 mRNA expression was decreased by almost 90% compared to scramble 48 h after transfection of siMYC (Fig. 3B) .
EZH2 inhibitors decrease H3K27me3 in medulloblastoma cell lines
Next, we sought to determine whether pharmacological EZH2 blockade would inhibit H3K27me3 levels. Several second generation EZH2 inhibitors, showing more selective anti-EZH2 effects compared to DZNep, have been produced. 17 Potency at nanomolar concentrations has been observed in diffuse large B cell lymphomas with EZH2-activating mutations. 18 One study noted superior brain penetrance of EPZ6438 in an intracranial breast cancer metastasis model. 19 We decided to use this drug and GSK343, a new and potent selective EZH2 inhibitor with improved membrane permeability compared to the previously available GSK126. 19 Both 200 nmol/L of EPZ6438 and 200 nmol/L of GSK343 robustly decreased H3K27me3 protein levels in UW228, UW228-MYC, DAOY, DAOY-MYC and D425 (Fig. 3C) .
EZH2 inhibitors decrease cell growth and induce apoptosis in some high MYC medulloblastoma lines
We next sought to determine whether EZH2 inhibitors would inhibit cell growth in high MYC medulloblastomas.
We treated DAOY, DAOY-MYC, UW228 and UW228-MYC cells for up to 120 h with 200 nmol/L of EPZ6438 and GSK343. DAOY-MYC was more sensitive to treatment with EPZ6438 compared to DAOY (Fig. 4A) . However, while UW228-MYC was quite sensitive to 200 nmol/L treatment of both EPZ6438 and GSK343, the UW228 parent line with low MYC showed an almost equivalent response (Fig. 4B ). D425 cultures with high MYC levels were also very sensitive to both EZH2 inhibitors (Fig. 4C) .
The differences in growth response of DAOY and UW228 to EZH2 inhibitors as measured by MTS assays may be due at least in part to effects on proliferation. EPZ6438 caused a greater reduction in the Ki67 index in DAOY-MYC cells (94% to 39%) than in the DAOY parent line (94% to 51%), while both UW228 and UW228-DAOY showed similar responses (Additional file: Fig. S1 ).
Apoptosis assays showed an approximately 50% increase of Annexin V-positive cells after 72-h treatment with 200 nmol/L EPZ6438 in both DAOY-MYC and UW228-MYC (Additional file: Fig. S2 ), consistent with a previously published study using EZH2 inhibitors in neuroblastoma lines. 
DISCUSSION
MYC and MYCN amplification in medulloblastoma has long been associated with anaplastic histopathological features and more aggressive clinical behavior. In this study, we examined whether MYC expression might regulate EZH2 and H3K27me3 levels, or be associated with response to EZH2 inhibitors. We report that in multiple medulloblastoma models in vitro, increased MYC is associated with elevation of EZH2 and H3K27me3. Analyzing formalin-fixed specimens using immunohistochemistry, we found that Group 3 and Group 4 medulloblastomas had high levels of H3K27me3. However, this did not significantly correlate with MYC protein, suggesting that in vivo factors other than MYC can also regulate H3K27 methylation status.
Ongoing work has further refined our understanding of how these oncogenes relate to medulloblastoma biology. A newly proposed molecular classification divides the original four groups into 12 molecular subgroups. According to the proposed scheme, MYC amplification is noted in a subset of Group 3 (Group 3 γ), MYCN amplification in a subset of Group 4 (Group 4 α) and SHH-activated group (SHH α).
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All three subsets, especially the MYC-amplified Group 3 cases, are considered to have poor prognoses. 2, 3, 21 H3K27me3 (Fig. 2C) , 5, 7 and EZH2 expression 6, 7 are high in Groups 3 and 4. Medulloblastomas with elevated MYC/MYCN, EZH2 and H3K27me3 have poor prognoses, making novel therapies of these tumors a priority. BET bromodomain inhibitors have been shown to be effective in MYC-amplified medulloblastoma, 22 and we were able to show that further downstream targeting of MYC by EZH2 inhibition is also effective in these tumors. "DiSCoVER" in silico drug screening we previously reported revealed EZH2 inhibitors as a potentially effective therapeutic drug in the high-MYC medulloblastoma model, 4 further validating the results of the current study. Our findings complement those of Taylor et al., who reported the effectiveness of EZH2 inhibitors in medulloblastoma but did not examine if MYC expression was predictive of responsiveness. 6 The efficacy of EZH2 inhibitors have been suggested in multiple brain tumors, including gliomas, [23] [24] [25] atypical teratoid rhabdoid tumors (ATRT), 26 and diffuse intrinsic pontine gliomas (DIPGs).
27 Surprisingly, DIPGs are known to have decreased total EZH2 expression, but H3K27me3 was found to be upregulated in select genomic regions. 27, 28 This could possibly explain why EZH2 inhibitors were somewhat effective in low-MYC cell lines in the current study, and further investigation of the exact distribution of EZH2 is necessary. In this study, we found that EZH2 inhibitors were more effective in high-MYC medulloblastoma lines.
We tested the ability of the EZH2 inhibitor to slow the growth of two low MYC patient-derived medulloblastoma lines for which we had previously generated paired high MYC sublines. In the DAOY and DAOY-MYC pair, higher MYC expression was associated with prominent induction of EZH2, and the inhibitor was significantly more effective in slowing growth of the high MYC/EZH2 line. In UW228 cells, baseline EZH2 levels were very low, and only slightly induced by MYC. The EZH2 inhibitor shows statistically equivalent effects on growth, and the very low levels of its target raise the possibility of off-target effects. Furthermore, we performed knockdown of MYC using siRNA and found a decrease of EZH2 at the protein and mRNA levels (Fig. 3A, B) . H3K27me3 was also robustly decreased after treatment with the EZH2 inhibitors EPZ6438 and GSK343. These data are consistent with that from a previously published report testing EPZ6438 and GSK126 in neuroblastoma cell lines, 20 suggesting that EZH2 inhibitors alter the enzymatic activity but not protein expression of EZH2. Whether or not the main function of EZH2 inhibitors on MYC-amplified tumors is to inhibit EZH2 or decrease H3K27me3 levels remains to be seen.
In conclusion, our data establish a linkage between MYC and EZH2 in medulloblastomas, and support the concept that elevated MYC may be associated with increased efficacy of EZH2 inhibition. In vivo studies will be needed to further confirm this hypothesis. 
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